Intervention Review

Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis

  1. Edward F Nash1,*,
  2. Anne Stephenson2,
  3. Felix Ratjen3,
  4. Elizabeth Tullis4

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 27 OCT 2010

DOI: 10.1002/14651858.CD007168.pub2

How to Cite

Nash EF, Stephenson A, Ratjen F, Tullis E. Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD007168. DOI: 10.1002/14651858.CD007168.pub2.

Author Information

  1. 1

    Birmingham Heartlands Hospital, Department of Respiratory Medicine, Birmingham, UK

  2. 2

    St Michael's Hospital, Division of Respirology, Room 6-040, Toronto, Ontario, Canada

  3. 3

    The Hospital for Sick Children, Department of Pediatrics, Toronto, Ontario, Canada

  4. 4

    St Michael's Hospital, Respirology Program Director, Room 6-045, Toronto, Ontario, Canada

*Edward F Nash, Department of Respiratory Medicine, Birmingham Heartlands Hospital, Bordesley Green East, Birmingham, B9 5SS, UK. edward.nash@heartofengland.nhs.uk. ednash2000@hotmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

  1. Current Version

    Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis

    Edward F Nash, Anne Stephenson, Felix Ratjen and Elizabeth Tullis

    Article first published online: 21 JAN 2009 | DOI: 10.1002/14651858.CD007168.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Thiol derivatives for pulmonary disease in cystic fibrosis

    E Nash, A Stephenson, F Ratjen and E Tullis

    Article first published online: 8 OCT 2008 | DOI: 10.1002/14651858.CD007168